Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRTS NYSEAMERICAN:MYO NASDAQ:NYXH NASDAQ:STIM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRTSAlpha Tau Medical$2.98-2.9%$3.04$1.93▼$4.39$260.40M0.9939,828 shs12,473 shsMYOMyomo$1.87-3.1%$2.41$1.83▼$7.17$69.44M1.4407,453 shs331,230 shsNYXHNyxoah$7.30-2.1%$7.72$5.55▼$11.87$254.09M1.6143,328 shs60,727 shsSTIMNeuronetics$4.42+0.7%$3.79$0.52▼$5.92$290.24M1.78873,752 shs637,790 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRTSAlpha Tau Medical-2.93%-2.61%-5.99%+14.62%+36.70%MYOMyomo-3.11%-11.37%-10.10%-61.68%-64.24%NYXHNyxoah-2.14%-3.69%-5.19%+19.67%-12.68%STIMNeuronetics+0.68%-1.56%+29.24%-3.49%+136.36%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRTSAlpha Tau Medical1.7933 of 5 stars3.53.00.00.00.61.70.0MYOMyomo2.0796 of 5 stars3.52.00.00.00.62.50.6NYXHNyxoah2.5683 of 5 stars3.54.00.00.01.90.80.6STIMNeuronetics1.5217 of 5 stars2.31.00.00.03.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRTSAlpha Tau Medical 3.00Buy$8.00168.46% UpsideMYOMyomo 3.00Buy$9.67416.93% UpsideNYXHNyxoah 3.00Buy$14.5098.63% UpsideSTIMNeuronetics 2.67Moderate Buy$5.5024.43% UpsideCurrent Analyst Ratings BreakdownLatest MYO, NYXH, DRTS, and STIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025MYOMyomoAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/23/2025MYOMyomoCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$10.00 ➝ $8.006/5/2025MYOMyomoAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $11.505/8/2025MYOMyomoCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRTSAlpha Tau MedicalN/AN/AN/AN/A$0.89 per shareN/AMYOMyomo$32.55M2.07N/AN/A$0.82 per share2.28NYXHNyxoah$4.89M50.85N/AN/A$3.60 per share2.03STIMNeuronetics$74.89M3.90N/AN/A$0.57 per share7.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRTSAlpha Tau Medical-$31.75M-$0.46N/AN/AN/AN/A-49.48%-36.69%8/13/2025 (Estimated)MYOMyomo-$6.18M-$0.23N/AN/AN/A-15.05%-35.57%-20.11%8/5/2025 (Estimated)NYXHNyxoah-$64.10M-$2.13N/AN/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)STIMNeuronetics-$43.71M-$1.31N/AN/AN/A-53.67%-174.15%-38.41%8/5/2025 (Estimated)Latest MYO, NYXH, DRTS, and STIM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025DRTSAlpha Tau Medical-$0.12N/AN/AN/AN/AN/A8/5/2025Q2 2025MYOMyomo-$0.11N/AN/AN/A$9.15 millionN/A8/5/2025Q2 2025NYXHNyxoah-$0.60N/AN/AN/A$1.33 millionN/A8/5/2025Q2 2025STIMNeuronetics-$0.08N/AN/AN/A$36.80 millionN/A5/19/2025Q1 2025DRTSAlpha Tau Medical-$0.14-$0.12+$0.02-$0.12$0.03 millionN/A5/14/2025Q1 2025NYXHNyxoah-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million5/6/2025Q1 2025STIMNeuronetics-$0.13-$0.21-$0.08-$0.21$29.07 million$31.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRTSAlpha Tau MedicalN/AN/AN/AN/AN/AMYOMyomoN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRTSAlpha Tau Medical0.105.815.81MYOMyomoN/A2.662.37NYXHNyxoah0.223.593.35STIMNeuronetics1.402.442.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRTSAlpha Tau Medical2.65%MYOMyomo44.99%NYXHNyxoahN/ASTIMNeuronetics53.59%Insider OwnershipCompanyInsider OwnershipDRTSAlpha Tau Medical39.50%MYOMyomo4.79%NYXHNyxoah17.11%STIMNeuronetics8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataMYOMyomo9035.98 million34.26 millionNot OptionableNYXHNyxoah11034.06 million28.23 millionNot OptionableSTIMNeuronetics18066.11 million60.36 millionOptionableMYO, NYXH, DRTS, and STIM HeadlinesRecent News About These CompaniesNeuronetics (STIM) Projected to Post Earnings on TuesdayJuly 30 at 11:41 AM | marketbeat.comNeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed AdolescentsJuly 30 at 8:32 AM | globenewswire.comKestra Private Wealth Services LLC Purchases Shares of 68,977 Neuronetics, Inc. (NASDAQ:STIM)July 29, 2025 | marketbeat.comNkcfo LLC Takes Position in Neuronetics, Inc. (NASDAQ:STIM)July 28, 2025 | marketbeat.comCenterBook Partners LP Invests $1.20 Million in Neuronetics, Inc. (NASDAQ:STIM)July 17, 2025 | marketbeat.comNeuronetics taps local industry veteran as new CFOJuly 15, 2025 | bizjournals.comNeuronetics Names Pfanstiel as CFO to Succeed FurlongJuly 15, 2025 | marketwatch.comNeuronetics Appoints New Chief Financial OfficerJuly 15, 2025 | finance.yahoo.comNeuronetics names Steven Pfanstiel chief financial officerJuly 15, 2025 | massdevice.comNeuronetics Appoints New Chief Financial OfficerJuly 15, 2025 | globenewswire.comNeuronetics Showcases NeuroStar TMS Data at Clinical TMS MeetingJuly 10, 2025 | msn.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 19, 2025 | globenewswire.comNeuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial ProgramJune 10, 2025 | globenewswire.comNeuronetics, Inc. to Join Russell 3000® and Russell 2000® Indexes Effective June 30, 2025June 3, 2025 | nasdaq.comNeuronetics to join Russell 3000 and Russell 2000 indexesJune 2, 2025 | msn.comNeuronetics Set to Join Russell 2000® and Russell 3000® IndexesJune 2, 2025 | globenewswire.comNeuronetics, Inc. (NASDAQ:STIM) EVP Sells $826,074.20 in StockMay 15, 2025 | insidertrades.comNeuronetics Launches First Inaugural National TMS Therapy Awareness Day During Mental Health Awareness MonthMay 14, 2025 | tmcnet.comNeuronetics Announces Inducement Awards for New Team MembersMay 10, 2025 | msn.comNeuronetics, Inc. (NASDAQ:STIM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$6.83May 9, 2025 | finance.yahoo.comEarnings call transcript: Neuronetics Q1 2025 misses EPS, stock drops 22%May 7, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYO, NYXH, DRTS, and STIM Company DescriptionsAlpha Tau Medical NASDAQ:DRTS$2.98 -0.09 (-2.93%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$2.98 0.00 (0.00%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Myomo NYSEAMERICAN:MYO$1.87 -0.06 (-3.11%) Closing price 08/1/2025 04:10 PM EasternExtended Trading$1.88 +0.01 (+0.59%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.Nyxoah NASDAQ:NYXH$7.30 -0.16 (-2.14%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.30 0.00 (-0.07%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Neuronetics NASDAQ:STIM$4.42 +0.03 (+0.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.43 +0.01 (+0.23%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
